◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Apogee Therapeutics, Inc. (APGE) Net Income 2022–2025
DATA UPDATED 2026-07-26
Apogee Therapeutics, Inc. annual net income for fiscal 2025 was -$256 million, a decrease of 40.5% from -$182 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
APGE Annual Net Income
| Net Income (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|
| Net Income | ($256M) | ($182M) | ($84M) | ($40M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
APGE Quarterly Net Income
| Net Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|
| Net Income | ($74M) | ($69M) | ($65M) | ($66M) | ($55M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More APGE metrics: Revenue · Operating Income · EPS · Free Cash Flow
All APGE financial statements → Interactive APGE charts →
About TickerBase · Data methodology & sources
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.